Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Protagonist Therapeutics Inc (NASDAQ: PTGX) closed at $50.21 down -9.16% from its previous closing price of $55.27. In other words, the price has decreased by -$9.16 from its previous closing price. On the day, 1.51 million shares were traded. PTGX stock price reached its highest trading level at $55.675 during the session, while it also had its lowest trading level at $49.92.
Ratios:
For a deeper understanding of Protagonist Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.42 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.28. For the most recent quarter (mrq), Quick Ratio is recorded 17.26 and its Current Ratio is at 17.26. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on June 17, 2025, initiated with a Buy rating and assigned the stock a target price of $72.
On December 06, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $47.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $62.BMO Capital Markets initiated its Outperform rating on December 06, 2024, with a $62 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 10 ’25 when MOLINA ARTURO MD sold 10,000 shares for $57.03 per share. The transaction valued at 570,300 led to the insider holds 83,892 shares of the business.
MOLINA ARTURO MD sold 10,000 shares of PTGX for $555,100 on Jun 09 ’25. The Chief Medical Officer now owns 83,892 shares after completing the transaction at $55.51 per share. On Jun 10 ’25, another insider, ARTURO MOLINA, who serves as the Officer of the company, bought 10,000 shares for $57.03 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 3112116224 and an Enterprise Value of 2862742528. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 66.00. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.98 while its Price-to-Book (P/B) ratio in mrq is 4.51. Its current Enterprise Value per Revenue stands at 13.776 whereas that against EBITDA is 102.048.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.26, which has changed by 0.45536232 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $60.60, while it has fallen to a 52-week low of $32.50. The 50-Day Moving Average of the stock is 2.69%, while the 200-Day Moving Average is calculated to be 12.51%.
Shares Statistics:
For the past three months, PTGX has traded an average of 1.04M shares per day and 1137610 over the past ten days. A total of 61.93M shares are outstanding, with a floating share count of 58.35M. Insiders hold about 5.86% of the company’s shares, while institutions hold 102.38% stake in the company. Shares short for PTGX as of 1749772800 were 5913322 with a Short Ratio of 5.70, compared to 1747267200 on 5287293. Therefore, it implies a Short% of Shares Outstanding of 5913322 and a Short% of Float of 11.450000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Protagonist Therapeutics Inc (PTGX) is currently being evaluated by a team of 9.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.3 and low estimates of -$0.72.
Analysts are recommending an EPS of between -$0.29 and -$2.52 for the fiscal current year, implying an average EPS of -$1.65. EPS for the following year is -$1.17, with 9.0 analysts recommending between $2.75 and -$3.71.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for PTGX’s current fiscal year. The highest revenue estimate was $253.4M, while the lowest revenue estimate was $28.3M, resulting in an average revenue estimate of $81.31M. In the same quarter a year ago, actual revenue was $434.43M
